Welcome to our dedicated page for Onco-Innovations news (Ticker: ONNVF), a resource for investors and traders seeking the latest updates and insights on Onco-Innovations stock.
News for Onco-Innovations Limited (ONNVF) centers on its activities in oncology research, preclinical drug development, AI-enabled precision medicine, and corporate financing. The company describes itself as a Canadian-based oncology-focused organization with an exclusive worldwide license to patented technology targeting solid tumours, including its PNKP Inhibitor Technology platform.
Investors and observers following Onco-Innovations’ news can expect updates on the advancement of its PNKP Inhibitor Technology (A83B4C63), including manufacturing milestones with Dalton Pharma Services such as process optimization, intermediate scale-up, analytical method development, and preparation for potential future clinical material production. Releases also cover collaborations with partners like Kuano Ltd., where quantum-ready molecular modelling and AI-driven compound design are being applied to deepen understanding of PNKP inhibition and guide next-generation therapeutic candidates.
Another important stream of news involves Onco-Innovations’ subsidiary Inka Health and its SynoGraph platform. Announcements have highlighted publications on the transportability of real-world evidence, integration of advanced statistical methods into SynoGraph, and participation in precision oncology forums with organizations such as Colorectal Cancer Canada. These items illustrate how the company links AI, real-world data, and oncology decision-making.
Corporate and capital markets developments also feature in the news flow. Onco-Innovations has reported private placements, board appointments, marketing engagements, and its intention to pursue a potential Nasdaq cross-listing with the support of a U.S. investment bank. For a consolidated view of these scientific, strategic, and financing updates, this news page provides a single location to review the company’s disclosed developments over time.
Onco-Innovations (OTCQB:ONNVF) has successfully closed its previously announced non-brokered private placement, raising $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at $2.05 per share until August 13, 2028.
The company will utilize the proceeds for general corporate and working capital purposes, including operational and R&D objectives. Additionally, 2,439 administrative shares were issued to a third party for services related to the placement. All securities are subject to a four-month hold period ending December 14, 2025.
Onco-Innovations (OTCQB:ONNVF) has signed a Start-Up Agreement with Avance Clinical to prepare for its first-in-human trial of their novel PNKP inhibitor therapy. The agreement focuses on developing crucial regulatory and clinical documentation required for human testing approvals.
Under the partnership, Avance will provide comprehensive support including: development of an Investigator's Brochure, creation of clinical trial protocols, conducting nonclinical gap analysis, and preparation for a pre-IND meeting with the FDA. The therapy targets advanced-stage cancers with PTEN1 or SHP-12 deficiency.
Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.
The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.
The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.
Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement to raise up to $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $2.05 for 36 months.
The company will issue additional shares as a 1% administrative fee to a third party. Additionally, Onco-Innovations has approved the grant of 119,785 stock options and 960,000 restricted share units (RSUs) under its equity incentive plan. The proceeds will support general corporate purposes and R&D objectives.
Onco-Innovations (CBOE CA:ONCO) has appointed renowned chemist Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a Professor of Chemistry at the University of Alberta and Tier 1 Canada Research Chair in Boron Chemistry, brings extensive expertise in organoboron chemistry, catalysis, and medicinal chemistry.
Dr. Hall's impressive credentials include over 175 peer-reviewed publications, 18,000+ citations, and numerous prestigious awards. He will provide strategic guidance on the company's R&D initiatives, particularly focusing on the development of PNKP Inhibitor Technology NP/A83 for oncology applications.
Onco-Innovations (OTCQB:ONNVF) has entered into a services agreement with Redwood AI to advance the development of its exclusively-licensed Polynucleotide Kinase Phosphatase (PNKP) Compound technology. The collaboration aims to enhance the company's drug development capabilities through AI-driven chemistry tools.
The partnership will leverage Redwood AI's expertise in synthesis evaluation, cheminformatics, and organ-specific toxicity prediction for the PNKP technology. The proprietary compound targets solid tumors by increasing sensitivity to radiation and DNA-damaging chemotherapies. This strategic collaboration is designed to support Onco's progression toward First-in-Human studies by improving scalability, safety, and discovery precision.
Onco-Innovations (CBOE CA:ONCO) has appointed Dr. Islam Mohamed as Chair of its Scientific and Clinical Advisory Board. Dr. Mohamed brings over 20 years of experience as a Radiation Oncologist, clinical researcher, and biotechnology advisor.
Dr. Mohamed's expertise spans lung, breast, skin cancers, and sarcoma treatment at BC Cancer, with significant experience in stereotactic radiation delivery. He has led numerous clinical trials and served on research ethics boards and national committees. His role will involve providing strategic guidance on R&D initiatives and facilitating clinical and scientific collaboration.
Onco-Innovations (OTCQB:ONNVF) has signed a crucial agreement with Nucro-Technics to conduct IND-enabling preclinical studies for its lead drug candidate. The studies will focus on the company's PNKP inhibitor (NP/A83), which targets advanced-stage, PTEN- or SHP-1-deficient cancers.
The comprehensive testing program includes drug metabolism testing (ADME studies) and GLP-compliant safety studies required for regulatory approval. Nucro-Technics, a Toronto-based CRO with 55 years of experience, will evaluate the drug's bioavailability, biodistribution, pharmacokinetics, and safety profile to support future IND applications with both FDA and Health Canada.
The agreement represents a significant milestone toward initiating Phase I/II clinical trials, including validation of analytical methods and safety assessment of the novel polymer delivery system (mPEO-bPBCL).
Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy provided a comprehensive update on the company's strategic developments and R&D progress during a special investor call. Key highlights include the advancement of their PNKP Inhibitor Technology with Dalton Pharma Services for preclinical testing, and progress in the PROmAI consortium with potential AstraZeneca participation.
The company has established a new research agreement with the University of Alberta and Cross Cancer Institute to study PNKP inhibition in glioblastoma multiforme. Following their February 2025 acquisition of Inka Health AI and May 2025 uplisting to Cboe Canada, Onco-Innovations continues to integrate AI capabilities into drug development through Inka's Synograph system.
Onco-Innovations (CBOE CA:ONCO) announced that its subsidiary, Inka Health, has received an Expression of Interest (EOI) from AstraZeneca to join as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium.
The PROmAI Consortium, led by Inka Health, aims to advance AI methodologies in oncology by combining real-world and clinical trial data with causal AI techniques. The initiative focuses on improving predictive modeling in cancer research, particularly during the transition from early- to late-phase clinical development.
AstraZeneca's involvement will include participation in the exploratory phase, encompassing joint planning discussions, project direction input, and strategic alignment around key use cases. Inka Health is currently in discussions with other global pharmaceutical companies for potential consortium participation.